TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06689839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F2 Filter and Delivery System
Description: Use of the F2 Filter and Delivery System in conjunction with a Transcatheter Aortic Valve Replacement (TAVR) procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter Aortic Valve Replacement (TAVR)
Description: Transcatheter Aortic Valve Replacement (TAVR) with commercially available Transcatheter Aortic Valve Replacement (TAVR) device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Replacement (TAVR)
Description: Transcatheter Aortic Valve Replacement (TAVR) with commercially available Transcatheter Aortic Valve Replacement (TAVR) device
Study: NCT06689059

Intervention type: OTHER
Intervention: Multimodal Data Integration and Multi-Task Learning
Description: This study utilizes a multimodal data integration and multi-task learning approach to predict perioperative events after hip replacement surgery. By combining various data types, including demographics, surgical details, medical history, and lab results, the model enhances prediction accuracy for outcomes like AKI, blood transfusion needs, and ICU transfers. The use of ensemble learning algorithms such as CatBoost optimizes the platform's performance, offering a unique method for clinical decision support.
Study: NCT06693063

Intervention type: OTHER
Intervention: Data collection
Description: Some data will be collected for all patients included: medical and family history, chest pain data and medical care data

Intervention type: OTHER
Intervention: Data collection
Description: Some data will be collected for all patients included: medical and family history, chest pain data and medical care data
Study: NCT06693466

Intervention type: OTHER
Intervention: Facial expression block
Description: Data will be collected to assess the facial expression, body movements and vocalization of (non-) painful heat stimuli. The experiment includes individually tailored and randomly administered painful (perceived as moderate pain) and non-painful heat stimuli.

Intervention type: OTHER
Intervention: Facial expression block
Description: Data will be collected to assess the facial expression, body movements and vocalization of (non-) painful heat stimuli. The experiment includes individually tailored and randomly administered painful (perceived as moderate pain) and non-painful heat stimuli.

Intervention type: OTHER
Intervention: Conditioned pain modulation block
Description: The conditioned pain modulation will be tested according to internationally agreed standards and includes a painful phasic heat (test stimulus) and a painful tonic cold stimulus (conditioning stimulus).

Intervention type: OTHER
Intervention: Conditioned pain modulation block
Description: The conditioned pain modulation will be tested according to internationally agreed standards and includes a painful phasic heat (test stimulus) and a painful tonic cold stimulus (conditioning stimulus).

Intervention type: OTHER
Intervention: Pain facilitation block
Description: Pain facilitation will be assessed by using painful mechanical pinprick stimuli. The magnitude of pain experienced after a single mechanical pinprick stimulus is compared to that of a train of 10 pinprick stimuli of the same force.

Intervention type: OTHER
Intervention: Pain facilitation block
Description: Pain facilitation will be assessed by using painful mechanical pinprick stimuli. The magnitude of pain experienced after a single mechanical pinprick stimulus is compared to that of a train of 10 pinprick stimuli of the same force.
Study: NCT06691698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Cognitive Orientation to Daily Occupational Performance Approach
Description: CO-OP is a client-centred, performance-based, problem-solving focused, occupation-focused and occupation-based intervention. In CO-OP the person is guided to use a meta-cognitive strategy to find his or her own strategies for specific activities. The main purpose is to enable meta-cognitive thinking in every day activities, leading to enhanced self-efficacy, occupational performance and independency.
Study: NCT04647864

Intervention type: DEVICE
Intervention: Transcatheter Aortic Valve Implantation
Description: Replacement of the aortic valve of the heart through the blood vessels, delivered via one of several access methods.

Intervention type: DEVICE
Intervention: Transcatheter Aortic Valve Implantation
Description: Replacement of the aortic valve of the heart through the blood vessels, delivered via one of several access methods.

Intervention type: DEVICE
Intervention: Transcatheter Aortic Valve Implantation
Description: Replacement of the aortic valve of the heart through the blood vessels, delivered via one of several access methods.
Study: NCT04768777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural intervention for physical activity for multiple sclerosis (BIPAMS)
Description: The current behavioral intervention consists of two primary components; an internet website and one-on-one video chats with a behavioral coach. The internet website involves content delivered through interactive video courses.The interactive video courses are based on elements of social cognitive theory. Each course consists of an introduction, the primary content, and a take home message.The interactive courses include embedded, supplementary options such as videos on content and worksheets related to the topic.A pedometer is provided for tracking steps, and these steps will be entered into the website so progress can be monitored. The chats support adherence to the intervention,discussion of website material,supportive accountability,and reporting of adverse events/injuries. The chats are conducted face-to-face through an online videoconferencing platform. There are a total of 12 chats over 16 weeks. Chats occur on weeks 1-8, 10-11, 13 and16.
Study: NCT06719011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0174-1213 A
Description: Participants will be randomized to receive NNC0174-1213 A administered as subcutaneous (s.c. under the skin) injection.~Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0174-1213 A
Description: Participants will be randomized to receive NNC0174-1213 A administered as subcutaneous (s.c. under the skin) injection.~Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0174-1213 A
Description: Participants will be randomized to receive NNC0174-1213 A administered as subcutaneous (s.c. under the skin) injection.~Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0174-1213 A
Description: Participants will be randomized to receive NNC0174-1213 A administered as subcutaneous (s.c. under the skin) injection.~Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0174-1213 A
Description: Participants will be randomized to receive NNC0174-1213 A administered as subcutaneous (s.c. under the skin) injection.~Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0174-1213 A
Description: Participants will be randomized to receive NNC0174-1213 A administered as subcutaneous (s.c. under the skin) injection.~Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide B
Description: Participants will be randomized to receive Cagrilintide B administered as subcutaneous (s.c. under the skin) injection.~Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide B
Description: Participants will be randomized to receive Cagrilintide B administered as subcutaneous (s.c. under the skin) injection.~Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts.
Study: NCT06338631

Intervention type: OTHER
Intervention: Diet
Description: Pesonalized diet plan, devoloped according to Guidelines for dietary treatment of obesity, to be followed for a duration of 12 months
Study: NCT06719011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide B
Description: Participants will be randomized to receive Cagrilintide B administered as subcutaneous (s.c. under the skin) injection.~Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide B
Description: Participants will be randomized to receive Cagrilintide B administered as subcutaneous (s.c. under the skin) injection.~Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide B
Description: Participants will be randomized to receive Cagrilintide B administered as subcutaneous (s.c. under the skin) injection.~Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts.
Study: NCT06719011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide B
Description: Participants will be randomized to receive Cagrilintide B administered as subcutaneous (s.c. under the skin) injection.~Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo A (NNC0174 1213 A)
Description: Participants will be randomized to receive Placebo administered as subcutaneous (s.c. under the skin) injection.~Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo A (NNC0174 1213 A)
Description: Participants will be randomized to receive Placebo administered as subcutaneous (s.c. under the skin) injection.~Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo A (NNC0174 1213 A)
Description: Participants will be randomized to receive Placebo administered as subcutaneous (s.c. under the skin) injection.~Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo A (NNC0174 1213 A)
Description: Participants will be randomized to receive Placebo administered as subcutaneous (s.c. under the skin) injection.~Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo A (NNC0174 1213 A)
Description: Participants will be randomized to receive Placebo administered as subcutaneous (s.c. under the skin) injection.~Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo A (NNC0174 1213 A)
Description: Participants will be randomized to receive Placebo administered as subcutaneous (s.c. under the skin) injection.~Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts.
Study: NCT06718244

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: single dose of Inaticabtagene autoleucel
Description: Inaticabtagene autoleucel will be transfusioned intravenously at the recommended dose of 0.5×10\^8 (ranging 0.2-0.6×10\^8) viable CAR-T cells.
Study: NCT06746714

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive population care (active application of HOAP principles in patients flagged as high risk for hypoglycemia)
Description: The Hypoglycemia Champion (HC) pharmacist reviewed patient charts before conducting proactive outreach. They did not contact subjects with active psychiatric issues or those admitted to a skilled nursing facility. The patient's care team (PCP and APM) were also contacted for peer consent. The outreach process involved an initial phone call with a secure electronic message or mailed letter (for those without secure KPNC patient portal access) if the initial call was unsuccessful. A second and third phone call attempt was made for non-responders.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care, after system-side dissemination of HOAP
Description: Patients had their diabetes treated as usual by their diabetes care provider or primary care physician, after system-wide dissemination of HOAP.
Study: NCT06746818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Math interventions
Description: . The key components of Heart Math interventions include:~1. Heart Rate Variability (HRV) Training: This involves biofeedback techniques to help individuals learn how to control their heart rate and promote emotional balance.~2. Quick Coherence Technique: Participants are guided through a series of steps to shift their emotional state from stress to calmness, facilitating a sense of peace and emotional clarity.~3. Focus on Positive Emotions: Encouraging individuals to cultivate feelings like gratitude and compassion can enhance resilience and overall mental well-being.~4. Mindfulness Practices: Incorporating mindfulness helps individuals become more aware of their thoughts and feelings, allowing them to respond to stressors more effectively.
Study: NCT06747806

Intervention type: PROCEDURE
Intervention: Cardiac Surgery and Procedures
Description: To assess blood and tissue biomarkers of patients undergoing cardiac surgery
Study: NCT06742047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Professional development programme
Description: The professional development programme include dialogue groups facilitated by registered nurses (RN) who are expert and experienced supervisors that received a three day training before conducting the groups. Then including education days with joint lectures and simulations with experts in the field with experience. The programme provides NGNs with regular opportunities for reflection for learning from experiences of care to enhance personal and professional growth.
Study: NCT06746025

Intervention type: BEHAVIORAL
Intervention: Quit Center cessation program
Description: Lifestyle modifications based on the Quit Center cessation program.
Study: NCT05945225

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonicare DiamondClean 9000 Philips®
Description: Brush teeth with the electric toothbrush daily during 3 months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HydroSonic Easy Curaden®
Description: Brush teeth with the hydrosonic toothbrush daily during 3 months

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Manual toothbrush Oral-B 123
Description: Brush teeth with the manual toothbrush daily during 3 months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual toothbrush Curaprox CS 5460
Description: Brush teeth with the manual toothbrush daily during 3 months
Study: NCT06501196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH-30236
Description: BH-30236 will be provided as either a 5 or 30 mg tablet. Patients will take BH-30236 orally depending on their dose level assignment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH-30236
Description: BH-30236 will be provided as either a 5 or 30 mg tablet. Patients will take BH-30236 orally depending on their dose level assignment.
Study: NCT05634343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental group 1
Description: Laughter therapy, also called therapeutic laughter, is used to relieve pain and stress and to promote a general sense of well-being. Laughter therapy is simply a method of 'laughing for no reason' in which the person interacts in a group setting with improvisation or pantomime-like exercises and childish games without humour, jokes or funny events. The aim is thus to benefit from laughter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimantal group 2
Description: Mindfulness is purposefully drawing attention in the desired direction so that we can stay in the present moment without judgment. It is also defined as a conscious understanding of what is happening in the moment we live in with an open and loving attitude. According to another definition, mindfulness includes paying attention to what is happening in the present moment, noticing the quality of this attention, and accepting what is noticed without judgment. With conscious awareness, the individual discovers how to live in harmony with all the events that take place in the present moment, place and time, without any evaluation, rather than the sorrows and regrets of the past, the anxieties and worries of the future. Mindfulness helps us to relate to our experiences by enabling us to see the positive-negative, good-bad experiences we have had objectively.
Study: NCT05991453

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anesthetic technique Propofol TIVA
Description: Propofol TIVA no inhaled agent

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anesthetic technique inhaled agent
Description: Must administer inhaled agent.
Study: NCT06277284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MG-K10 humanized monoclonal antibody injection (prefilled syringe)
Description: MG-K10 Humanized Monoclonal Antibody Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MG-K10 humanized monoclonal antibody injection（Penicillin bottle）
Description: MG-K10 humanized monoclonal antibody injection (single injection)
Study: NCT05036109

Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin
Description: by mouth every day for up to 90 days

Intervention type: DRUG
Group type: OTHER
Intervention: Vitamin D
Description: by mouth every day for up to 90 days

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Diet
Description: Patients will receive counseling promoting a plant-based diet and avoidance of Western dietary patterns in a one on one session with a licensed dietitian prior to day 1.

Intervention type: OTHER
Group type: OTHER
Intervention: Physical Activity
Description: The exercise goal is to increase recreational physical activity from baseline by at least 10 MET hours per week, which is equivalent to 150 minutes of moderate activity weekly

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral Support Counseling Sessions
Description: Patients will undergo a one-on-one counseling session prior to day 1
Study: NCT05838287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Participants will be taking Pioglitazone tablets 1/day for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Pioglitazone
Study: NCT06545552

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: An oral formulation of green tea extract, bamboo shoot extract and selenium-enriched yeast
Description: Hard shell capsule containing 280mg of the oral formulation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Hard shell capsule containing maltodextrine
Study: NCT06631508

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative Period, Postoperative Period, 2th week after discharge, 6th week after discharge, 10th week after discharge, 14th week after discharge
Description: Showing training videos to patients before and after pelvic organ prolapse surgery and following up after discharge
Study: NCT05727501

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post isometric relaxation
Description: post isometric relaxation in which 3-5 repetitions for 7-10 seconds hold in each session for three sessions per week in alternate days for four weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post facilitation stretching
Description: post facilitation stretching in which 3-5 repetitions for 7-10 seconds hold in each session for three sessions per week in alternate days for four weeks.
Study: NCT06631508

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative Period, Postoperative Period, 2th week after discharge, 6th week after discharge, 10th week after discharge, 14th week after discharge
Description: Showing training videos to patients before and after pelvic organ prolapse surgery and following up after discharge

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative Period, Postoperative Period, 2th week after discharge, 6th week after discharge, 10th week after discharge, 14th week after discharge
Description: Showing training videos to patients before and after pelvic organ prolapse surgery and following up after discharge

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative Period, Postoperative Period, 2th week after discharge, 6th week after discharge, 10th week after discharge, 14th week after discharge
Description: Showing training videos to patients before and after pelvic organ prolapse surgery and following up after discharge

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative Period, Postoperative Period, 2th week after discharge, 6th week after discharge, 10th week after discharge, 14th week after discharge
Description: Showing training videos to patients before and after pelvic organ prolapse surgery and following up after discharge

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative Period, Postoperative Period, 2th week after discharge, 6th week after discharge, 10th week after discharge, 14th week after discharge
Description: Showing training videos to patients before and after pelvic organ prolapse surgery and following up after discharge
Study: NCT06629090

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Participants will undergo an MRI scan while performing breathing and simulated postural change tasks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: A dose of prazosin will be administered based on body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral placebo
Study: NCT06631248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinative exercise protocol
Description: During the eight-week period, all children in the structured coordinative exercise intervention group participated in 30-minute sessions twice a week on the same day and time. The purpose-oriented basic movement patterns created in the coordinative exercise content were organised in a play-oriented manner suitable for the preschool age range.